Olympia Koulouri1, Andrea Steuwe1, Daniel Gillett1, Andrew C Hoole1, Andrew S Powlson1, Neil A Donnelly1, Neil G Burnet1, Nagui M Antoun1, Heok Cheow1, Richard J Mannion1, John D Pickard1, Mark Gurnell2. 1. Metabolic Research Laboratories Wellcome Trust-MRC Institute of Metabolic Science Departments of Nuclear Medicine Medical Physics Otolaryngology Oncology Neuroradiology Neurosurgery National Institute for Health Research, Cambridge Biomedical Research Centre, University of Cambridge & Addenbrooke's Hospital, Box 289, Hills Road, Cambridge CB2 0QQ, UK. 2. Metabolic Research Laboratories Wellcome Trust-MRC Institute of Metabolic Science Departments of Nuclear Medicine Medical Physics Otolaryngology Oncology Neuroradiology Neurosurgery National Institute for Health Research, Cambridge Biomedical Research Centre, University of Cambridge & Addenbrooke's Hospital, Box 289, Hills Road, Cambridge CB2 0QQ, UK mg299@medschl.cam.ac.uk.
Abstract
OBJECTIVE: We report our experience of functional imaging with (11)C-methionine positron emission tomography-computed tomography (PET-CT) co-registered with 3D gradient echo (spoiled gradient recalled (SPGR)) magnetic resonance imaging (MRI) in the investigation of ACTH-dependent Cushing's syndrome. DESIGN: Twenty patients with i) de novo Cushing's disease (CD, n=10), ii) residual or recurrent hypercortisolism following first pituitary surgery (±radiotherapy; n=8) or iii) ectopic Cushing's syndrome (n=2) were referred to our centre for functional imaging studies between 2010 and 2015. Six of the patients with de novo CD and five of those with persistent/relapsed disease had a suspected abnormality on conventional MRI. METHODS: All patients underwent (11)C-methionine PET-CT. For pituitary imaging, co-registration of PET-CT images with contemporaneous SPGR MRI (1 mm slice thickness) was performed, followed by detailed mapping of (11)C-methionine uptake across the sella in three planes (coronal, sagittal and axial). This allowed us to determine whether suspected adenomas seen on structural imaging exhibited focal tracer uptake on functional imaging. RESULTS: In seven of ten patients with de novo CD, asymmetric (11)C-methionine uptake was observed within the sella, which co-localized with the suspected site of a corticotroph microadenoma visualised on SPGR MRI (and which was subsequently confirmed histologically following successful transsphenoidal surgery (TSS)). Focal (11)C-methionine uptake that correlated with a suspected abnormality on pituitary MRI was seen in five of eight patients with residual or recurrent Cushing's syndrome following first TSS (and pituitary radiotherapy in two cases). Two patients elected to undergo repeat TSS with histology confirming a corticotroph tumour in each case. In two patients with the ectopic ACTH syndrome, (11)C-methionine was concentrated in sites of distant metastases, with minimal uptake in the sellar region. CONCLUSIONS: (11)C-methionine PET-CT can aid the detection of ACTH-secreting tumours in Cushing's syndrome and facilitate targeted therapy.
OBJECTIVE: We report our experience of functional imaging with (11)C-methionine positron emission tomography-computed tomography (PET-CT) co-registered with 3D gradient echo (spoiled gradient recalled (SPGR)) magnetic resonance imaging (MRI) in the investigation of ACTH-dependent Cushing's syndrome. DESIGN: Twenty patients with i) de novo Cushing's disease (CD, n=10), ii) residual or recurrent hypercortisolism following first pituitary surgery (±radiotherapy; n=8) or iii) ectopic Cushing's syndrome (n=2) were referred to our centre for functional imaging studies between 2010 and 2015. Six of the patients with de novo CD and five of those with persistent/relapsed disease had a suspected abnormality on conventional MRI. METHODS: All patients underwent (11)C-methionine PET-CT. For pituitary imaging, co-registration of PET-CT images with contemporaneous SPGR MRI (1 mm slice thickness) was performed, followed by detailed mapping of (11)C-methionine uptake across the sella in three planes (coronal, sagittal and axial). This allowed us to determine whether suspected adenomas seen on structural imaging exhibited focal tracer uptake on functional imaging. RESULTS: In seven of ten patients with de novo CD, asymmetric (11)C-methionine uptake was observed within the sella, which co-localized with the suspected site of a corticotroph microadenoma visualised on SPGR MRI (and which was subsequently confirmed histologically following successful transsphenoidal surgery (TSS)). Focal (11)C-methionine uptake that correlated with a suspected abnormality on pituitary MRI was seen in five of eight patients with residual or recurrent Cushing's syndrome following first TSS (and pituitary radiotherapy in two cases). Two patients elected to undergo repeat TSS with histology confirming a corticotroph tumour in each case. In two patients with the ectopic ACTH syndrome, (11)C-methionine was concentrated in sites of distant metastases, with minimal uptake in the sellar region. CONCLUSIONS: (11)C-methionine PET-CT can aid the detection of ACTH-secreting tumours in Cushing's syndrome and facilitate targeted therapy.
Authors: Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller Journal: Lancet Diabetes Endocrinol Date: 2021-10-20 Impact factor: 32.069
Authors: W A Bashari; D Gillett; J MacFarlane; A S Powlson; A G Kolias; R Mannion; D J Scoffings; I A Mendichovszky; J Jones; H K Cheow; O Koulouri; M Gurnell Journal: Pituitary Date: 2022-06-06 Impact factor: 3.599
Authors: Yang Liu; Ming Feng; Yong Yao; Kan Deng; Xinjie Bao; Xiaohai Liu; Renzhi Wang Journal: Medicine (Baltimore) Date: 2017-07 Impact factor: 1.889
Authors: Daniel Gillett; Russell Senanayake; James MacFarlane; Merel van der Meulen; Olympia Koulouri; Andrew S Powlson; Rosy Crawford; Bethany Gillett; Nick Bird; Sarah Heard; Angelos Kolias; Richard Mannion; Luigi Aloj; Iosif A Mendichovszky; Heok Cheow; Waiel A Bashari; Mark Gurnell Journal: EJNMMI Res Date: 2022-05-07 Impact factor: 3.434
Authors: Leah T Braun; German Rubinstein; Stephanie Zopp; Frederick Vogel; Christine Schmid-Tannwald; Montserrat Pazos Escudero; Jürgen Honegger; Roland Ladurner; Martin Reincke Journal: Endocrine Date: 2020-08-02 Impact factor: 3.633
Authors: José Miguel Hinojosa-Amaya; Elena V Varlamov; Shirley McCartney; Maria Fleseriu Journal: Front Endocrinol (Lausanne) Date: 2019-11-08 Impact factor: 5.555